Cargando…
Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study
BACKGROUND: Metastatic breast cancer (mBC) is a heterogenous disease with increasing availability of targeted therapies as well as emerging genomic markers of therapeutic resistance, necessitating timely and accurate molecular characterization of disease. As a minimally invasive test, analysis of ci...
Autores principales: | Zivanovic Bujak, Andjelija, Weng, Chen-Fang, Silva, Maria João, Yeung, Miriam, Lo, Louisa, Ftouni, Sarah, Litchfield, Cassandra, Ko, Yi-An, Kuykhoven, Keilly, Van Geelen, Courtney, Chandrashekar, Sushma, Dawson, Mark A., Loi, Sherene, Wong, Stephen Q., Dawson, Sarah-Jane |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529214/ https://www.ncbi.nlm.nih.gov/pubmed/33001984 http://dx.doi.org/10.1371/journal.pmed.1003363 |
Ejemplares similares
-
Clinical implications of prospective genomic profiling of metastatic breast cancer patients
por: van Geelen, Courtney T., et al.
Publicado: (2020) -
Correction to: Clinical implications of prospective genomic profiling of metastatic breast cancer patients
por: van Geelen, Courtney T., et al.
Publicado: (2022) -
Patient and Provider Perspectives on Enrollment in Precision Oncology Research: Qualitative Ethical Analysis
por: Spector-Bagdady, Kayte, et al.
Publicado: (2022) -
Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1/2 wildtype triple-negative breast cancer
por: Teo, Zhi Ling, et al.
Publicado: (2023) -
Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia
por: Yeh, Paul, et al.
Publicado: (2017)